Featured
Feeling disengaged? Here's what might be missing
An industry survey has uncovered the most important motivator for workplace engagement with more than 2300 open-ended comments pointing to one must-have
Featured
CSL names ex-Aussie GM as new CEO
After a global search, CSL has picked a 'world-class purpose-driven' high-flyer from a rival pharma to be its fourth CEO, bringing more than 25 years experience - including as an Australian GM - to the role
Government & Policy
Australia's long road to closing CAR T gap
Funding CAR T treatments isn't enough when structural barriers prevent the majority of referrals from accessing CAR T.
Industry & Companies
Aussie industry mega-event in full swing
Three flagship events brought together by AusBiotech for the first time is underway on the Gold Coast with more than 2500 expected to attend
Industry & Companies
Can doctors be bought for the price of a sandwich?
The more free meals a doctor receives from pharma, the more likely they are to prescribe less appropriate or more expensive drugs, according to a new review
Patients
Aussie patient groups speak up on pricing
New website reveals that Australian patients are among the most active in the world when it comes to taking their case for medicines access to drug-pricing regulators
Industry & Companies
Time-poor doctors move from papers to podcast
An Australian company is helping time-poor doctors stay up to speed with the latest research by turning clinical papers into podcasts with pharmas on board as sponsors
Industry & Companies
Takeover sends shares tumbling by 34%
This ASX-listed company has increased its stake to own two-thirds of a joint venture started two years ago but investors are not impressed
Industry & Companies
Bots move in at pharma logistics base
DHL has introduced advanced automation as part of a $9 million upgrade of its pharma facility in South-West Sydney
Featured
15 drugs jostle for November PBS listings
Among the 15-strong list are nine drugs vying to become the first to secure subsidy after being recommended at the PBAC's July 2026 meeting
Featured
Trump splurges on Big Pharma shares
The US President has come under scrutiny after boosting his pharma shareholdings by a breathtaking 3000 per cent last year. Find out which companies he's invested in and why it's caused controversy
Regulatory & Reimbursement
PBAC tweaks November Agenda
One submission withdrawn, a couple of newcomers join the list and a potentially eye-opening DUSC analysis deferred as PBAC readies for its next meeting in a fortnight
Industry & Companies
Roche stakes $22B bet on Chinese ADCs
The deal sees Roche take over late stage development and gain ex-China marketing rights for a range of ADCs.
Regulatory & Reimbursement
Rare disease drugs head for Australia
The TGA has handed out eight orphan drug designations in the past quarter, with three of them targeting the same kidney disease.
Industry & Companies
Who's scored a seat on the Medicines Australia Board?
Medicines Australia has named two high-profile company leaders as the newest additions to the Board, after Country Leadership changes mid-year resulted in departures
Jobs
-
Senior Territory Manager - Pharmacy QLD New
-
Warehouse Assistant & Forklift Driver New
-
Territory Manager New
-
National Sales Manager New
-
Regional Sales Manager New
-
Clinical Data Manager New
-
Corporate Accounts Lead New
-
Inventory Supervisor New
-
Market Access Lead New
-
Senior Clinical Research Associate (FSP) New
Government & Policy
Is it time for pharma to boycott PBAC?
A high-profile former Senior Health Department official turned patient advocate has called on the pharmaceutical industry to force the Government to take HTA reform seriously by withholding all submissions from the PBAC
Regulation & Legal
Counter-claim alleges false advertising by accuser
A bitter court battle is heating up with two companies now accusing each other of misleading advertising over claims about side effects and speed of absorption
Regulatory & Reimbursement
Second generic targets $113M drug
A second company has registered a copycat of a cancer drug across all tablet blister strengths, turning up the heat on the originator brand
Featured
Sept PBAC: Winners and Losers
Two out of three companies hoping to cut a path to a broad listing were told the preliminary info they provided didn't cut it, according to outcomes from September's Intracycle Meeting
Industry & Companies
How much do pharmas earn in Australia?
A report released by the ATO has revealed the total income declared in Australia for all pharmas who brought in at least a hundred million dollars. See the list
Regulation & Legal
HCP bungles trigger updates to two vaccine PIs
Product information updates for two jabs after reports of incorrect preparation and administration, which may result in the recall of patients for re-vaccination
Industry & Companies
Pharmas go on $11B buying binge
Five companies have splashed cash on new assets to build out their current portfolios, with one hoping a Virtual Human AI platform will uncover transformative therapeutics
Regulatory & Reimbursement
If you want a broad listing, ask the patients
The PBAC has updated the guidelines for pharmas seeking multi-cancer listings, looking for information beyond the clinical
Industry & Companies
It's official: this Aussie pharma knows how to celebrate
Recognised as a Great Place to Work for the fifth time, this company blitzed the benchmarks across four measures with a standout result for celebrating special events.
Latest
Leader flies a new flag for industry
After 30 years working in innovative medicine companies, the decision for Nikki Lorenz to become a champion of the generics and biosimilars industry was a surprisingly easy one
Regulation & Legal
Troubled $33M drug withdrawn from Australia
Following reports of eight deaths overseas, allegations trial results were manipulated plus regulatory action in the UK and Europe, this drug is coming off the market
Regulation & Legal
No fine after 'disparaging a rival' investigation
While this pharma has staved off a potentially hefty fine, it has agreed to a tough, legally binding agreement after an EU antitrust case
- Pipeline & Intellectual Property Roadblock hits plans to shore up the world's biggest drug
- Leadership & People Aussie GM reveals success secrets in new book
- Regulatory & Reimbursement Gene therapy rollout: Australia next in line?
- Patients Advocates fight to keep Richard Scolyer’s vision alive
- Government & Policy Fixing kids' medicine access in Australia
- Jobs & Workplace Why 'job hugging' is risky in pharma
- Pipeline & Intellectual Property Launch on hold pending legal fight
- Awards Aussie pioneer lands $50K Novo prize
- Jobs & Workplace Fresh starts dominate latest job moves
- Regulation & Legal J&J fails to exclude influencers in class action notice